Generation of genetically defined in situ liver cancers. (A) Technical outline. E-Cadherin-positive fetal liver progenitor cells (hepatoblasts) are purified and cultured as described above. Using the murine stem cell virus (MSCV) optimized to drive long-term gene expression in vivo, the cells are infected with oncogenes and/or shRNAs directed against tumor suppressor genes. After infection and expansion, the cells are transplanted into the spleens of conditioned recipient mice. Because all retroviral vectors used for infections are GFP-tagged, development of in situ HCCs can be monitored by external GFP imaging. (B) Schematic representation of the timeline of the approach. Mice undergo two pretreatments with the liver cell cycle inhibitor retrorsine. After transplantation of the cells into the spleen, the transplanted hepatoblasts are selectively expanded by CCl4 treatment of the mice. (C) GFP+ transplanted hepatoblasts can be detected in the recipient liver by anti-GFP immunofluorescence (right). H&E staining of an adjacent section of the liver (left). (D) External GFP imaging of a p53; c-myc tumor-bearing mouse (left). The GFP-positive spot in the square represents the intrahepatic tumor mass. The two additional spots (marked by asterisks) represent transplanted cells residing in the spleen after transplantation. Mice with advanced intrahepatic tumor growth present with swollen, ascites-containing abdomen allowing detection of tumor burden by palpation. GFP imaging of the explanted liver (bottom panel) reveals an advanced intrahepatic tumor, filling out a whole liver lobe. (E) Primary liver tumors can be outgrown in culture and retransplanted in situ into recipient mice. Shown is a tumor that was retransplanted by direct liver injection of 2 × 106 tumor cells. Note the extensive intrahepatic metastasis of the transplanted cells.